Latest Articles about DXCM

DexCom Loss Narrower than Est. - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 22:26:20 Z

DexCom, Inc. ( DXCM ), a player in the glucose monitoring market, reported first quarter 2013 adjusted loss per share of 16 cents, narrower than the Zacks Consensus Estimate of a loss of 17

DexCom Reports $1 Million Insider Buy

Monica Wolfe — Wed, 13 Mar 2013 03:10:30 Z

DexCom Inc. ( DXCM ) reported on Monday that Director, Dr. Jay Skyler, invested over $1 million back into DexCom. This marks the first insider buy for DexCom since March of last year.

Reiterate DexCom at Neutral - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 00:50:01 Z

On Feb 28, 2013, we retained DexCom ( DXCM ) at Neutral after the company beat Zacks Consensus Estimates for earnings and revenue for fourth quarter 2012. Why the Retention? DexCom

DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog

Zacks Equity Research — Fri, 22 Feb 2013 19:10:01 Z

DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth quarter 2012 adjusted loss per share of 14 cents, better than the Zacks Consensus Estimate of a loss of 16 cents

Earnings Preview: Medtronic - Analyst Blog

Mark Vickery — Fri, 15 Feb 2013 23:20:01 Z

We expect leading medical devices company - Medtronic ( MDT ) to beat expectations when it reports third-quarter 2013 results on Feb 19. Why a Likely Positive Surprise? Our proven

Still Neutral on DexCom - Analyst Blog

Zacks Equity Research — Thu, 15 Nov 2012 19:00:01 Z

Following the third quarter earnings release, we are maintaining our long-term 'Neutral' recommendation on DexCom ( DXCM ), a provider of continuous glucose monitoring systems, with a

DexCom Continues to Incur Loss - Analyst Blog

Zacks Equity Research — Mon, 05 Nov 2012 20:50:01 Z

DexCom ( DXCM ), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, higher than the Zacks Consensus Estimate of a loss of 22 cents per share

FDA Nod for Dexcom G4 Platinum - Analyst Blog

Zacks Equity Research — Fri, 12 Oct 2012 01:51:06 Z

DexCom ( DXCM ), a provider of continuous glucose monitoring systems, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its new continuous glucose monitoring

DexCom Remains Neutral - Analyst Blog

Zacks Equity Research — Mon, 27 Aug 2012 19:32:32 Z

We reiterate our Neutral recommendation on DexCom Inc. ( DXCM ). Its second-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus Estimate of a loss of 20 cents per share. Net

DexCom Misses on EPS, Losses Climb - Analyst Blog

Zacks Equity Research — Tue, 07 Aug 2012 18:21:48 Z

DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share

DexCom Wins CE Mark - Analyst Blog

Zacks Equity Research — Sat, 16 Jun 2012 00:52:10 Z

DexCom ( DXCM ), a player in the glucose monitoring market, recently reported that it received a CE Mark for its 4 th generation continuous glucose monitoring system. This recognition for

Echo Therapeutics to Join Russell Microcap Index - Analyst Blog

Zacks Equity Research — Thu, 14 Jun 2012 23:51:38 Z

On June 13, Echo Therapeutics ( ECTE ), a transdermal medical device company, announced that it anticipates being included in the Russell Microcap Index. It expects the inclusion on June 25,

DexCom Retained at Neutral - Analyst Blog

Zacks Equity Research — Mon, 11 Jun 2012 23:51:20 Z

We remain Neutral on DexCom ( DXCM ). Its first-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus Estimate. Losses widened year over year despite solid double-digit revenue

DexCom Misses on EPS, Losses Mount - Analyst Blog

Zacks Equity Research — Mon, 07 May 2012 18:17:01 Z

DexCom ( DXCM ), a player in the glucose monitoring market, reported first-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 19 cents per

Reaffirming DexCom at Neutral - Analyst Blog

Zacks Equity Research — Thu, 08 Mar 2012 20:15:01 Z

We remain Neutral on DexCom ( DXCM ), a prominent player in the continuous glucose monitoring market. Its fourth-quarter fiscal 2011 loss per share of 18 cents was a penny higher than